Clinical trial
Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen…
NCT00367640 · Stallergenes Greer, Industry · Completed
Key facts
| NCT number | NCT00367640 |
|---|---|
| Title | Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis |
| Official title | Randomised,Double-blind,Placebo-controlled,Multinational,Multi-centre,Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis |
| Lead sponsor | Stallergenes Greer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Drug |
| Interventions | 100 IR grass pollen allergen extract tablet, 300 IR grass pollen allergen extract tablet, 500 IR grass pollen allergen extract tablet, Placebo tablet |
| Enrollment | 628 |
| Start date | Nov 1, 2004 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Aug 23, 2006 |
| Last update posted | May 23, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: